Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Inclusion Criteria: * Histologically confirmed diagnosis of unresectable Stage IIIB or Stage IV relapsed or recurrent NSCLC. * Subjects must have: 1. documented (radiological or clinical) progressive disease (PD) following a prior response (including stable disease) to monotherapy with erlotinib or gefitinib that was administered for at least 12 weeks prior to progression OR 2. a documented T790M EGFR mutation * Measurable disease defined according to RECIST * ECOG performance status of 0 or 1. * Sexually active subjects must use an accepted method of contraception during the course of the study. * Female subjects of childbearing potential must have a negative pregnancy test at enrollment. Exclusion Criteria: * Received radiation to ≥25% of his or her bone marrow within 30 days of XL647 treatment. * Received erlotinib or gefitinib, or other anticancer therapy within 14 days of the first dose of study drug. * Received an investigational drug (excluding erlotinib or gefitinib) within 30 days of the first dose of study drug. * Receiving anticoagulation therapy with warfarin. * Not recovered to Grade ≤1 from adverse events (AEs) due to antineoplastic agents, investigational drugs, or other medications that were administered prior to study enrollment. * Corrected QT interval (QTc) of \>0.45 seconds. * Progressive, symptomatic, or hemorrhagic brain or leptomeningeal metastases. * Requires steroid or anticonvulsant therapy for the treatment of brain metastases.